The Procter & Gamble Company

01 — Executive summaryNet sales rose 3% to $87.0 billion. Unit volume rose zero. Both statements are correct.

The Procter & Gamble Company closed its fiscal year on 30 June 2026 having sold $87.0 billion of soap, shampoo, razors, diapers, detergent and toothpaste, three per cent more than the prior year. Over the same twelve months the number of units it shipped — cases, packs, bottles, tubes — did not increase at all. The volume line in the company's own sales-driver table reads zero for the second year running. Two points of the three points of reported growth came from foreign exchange. One point came from price. Nothing came from selling more product to more people.

That is the fact from which everything else in this report follows. P&G is not a company in difficulty. It generated $19.6 billion of operating cash flow and $15.1 billion of free cash flow in FY2026, returned $15.3 billion to shareholders, raised its dividend for the seventieth consecutive year, and holds a portfolio of brands — Tide, Ariel, Pampers, Gillette, Head & Shoulders, Pantene, Oral-B, Olay, Bounty, Charmin — that most consumer companies would trade their entire portfolio for. Return on invested capital was 21.5% and the balance sheet carries investment-grade debt at 1.4 times EBITDA.

But a consumer-staples franchise is bought for two things: a growing volume base and a reliable cash stream. P&G has spent five years building an outstanding record on the second and has now gone two years without the first. Worse, the mechanism that produced the growth it did report has become more expensive. Advertising expense rose from $9.2 billion to $10.2 billion — a billion dollars, an 11% increase — while organic sales growth halved from 2% to 1%. Operating margin fell 160 basis points to 22.7%. Net margin fell 60 basis points to 18.5%. And net margin narrowed in all five reportable segments without exception.

Management is candid about this. The letter to shareowners opens by conceding that fiscal 2026 was "another year of sales and earnings growth" delivered through "headwinds not anticipated at the start of the fiscal year," and closes the paragraph with the admission that "there is clearly more work to be done to sustain and accelerate the momentum underway." Chief executive Shailesh Jejurikar, who took the role on 1 January 2026, has reorganised the company around four interventions and a restructuring programme that will remove up to 7,000 non-manufacturing overhead positions by the end of fiscal 2027. The company is doing the right things. The question this report tries to answer is whether the price already assumes they will work.

We think it largely does. At $147.49 the shares trade on 22.0 times trailing earnings and 20.9 times forward earnings, for a business that guided to core EPS growth of between zero and three per cent in fiscal 2027, with a midpoint of 1.5%. The dividend yields 2.95%. The ten-year Treasury yields 5.31% — the highest since early 2002 — so the equity yields 236 basis points less than the risk-free asset. Even the free cash flow yield of 4.47% sits below the government bond. The valuation is not absurd; it is simply full.

To be clear about what we are not saying: this is not a thesis about a broken business. P&G's categories are mature and largely non-discretionary, its brands carry pricing power that has held through five years of inflation, and the productivity programme is real — the company took 460 basis points of gross productivity savings in the fourth quarter alone. The bear case that we take most seriously is not operational collapse; it is multiple compression. A 21-times multiple on two per cent earnings growth is a defensible price when the ten-year is at 2.5%. It is a much harder case to make when the ten-year is at 5.31% and the company's own dividend yields less than a bill.

Our twelve-month target is $150, which is 21.4 times our FY2027 core EPS estimate of $7.00 and implies a total return of roughly 4.7% including the dividend. We rate the shares Neutral. We would become constructive below about $130, which is where the free cash flow yield reaches 5% and the multiple falls to 18.5 times, or on two consecutive quarters of positive organic volume. We would become negative above $175, which is where the market would be capitalising an acceleration that has not yet appeared in a single month of scanner data.

Section 22 sets out the valuation in full, including a dividend discount sensitivity grid that shows the current price is supported only in the top-left corner of the plausible parameter space. Sections 23 and 24 set out the bull and bear cases at length, because on a name like this the honest answer is that both are coherent and the disagreement is about price rather than about the business. Section 25 ranks twelve risks by probability times impact. The remainder of the report works from the segment disclosures and the ten-K, and every figure in it is traceable to a primary source listed in section 29.

02 — Company & business modelFive categories where performance drives brand choice, and 180 countries where it is sold

P&G organises itself into five reportable segments under US GAAP, but it describes the business differently internally. The operating structure is built on four pieces: Sector Business Units, which own global brand strategy, innovation, marketing and supply chain; Enterprise Markets, which own local sales and profit delivery in the countries that are not designated Focus Markets; Corporate Functions; and Global Business Services. The Sector Business Units hold direct profit responsibility for the Focus Markets, which are the large majority of sales and earnings, and set the innovation and supply plans that the Enterprise Markets execute.

The distinction matters for anyone reading the segment tables. The five reportable segments — Beauty, Grooming, Health Care, Fabric & Home Care, and Baby, Feminine & Family Care — are product-based. The six geographic regions — North America, Europe, Greater China, Latin America, Asia Pacific and India, Middle East & Africa — are place-based. Neither maps cleanly onto the SBU/EM split that management actually runs, which is one reason the company's own commentary repeatedly moves between the two framings.

The portfolio is deliberately narrow by the standards of the sector. P&G competes in ten product categories — Fabric Care, Home Care, Baby Care, Feminine Care, Family Care, Hair Care, Skin & Personal Care, Oral Care, Personal Health Care and Grooming — and its stated strategic filter is that it will only stay in categories "where performance plays a significant role in the consumer's choice of brands." That sentence is doing a lot of work. It is why P&G owns Tide and Gillette and not, say, a bottled-water brand or a confectionery line, where taste and habit rather than demonstrable performance drive the purchase. It is also why the company has exited or is exiting a long list of businesses over the past decade.

The distribution model is retail-first. Products reach consumers through mass merchandisers, digital and social commerce, grocery, membership clubs, drug stores, department stores, distributors, wholesalers, specialty beauty stores including airport duty-free, high-frequency stores, pharmacies and professional channels, plus a direct-to-consumer business that is growing but is not separately disclosed. E-commerce was 20% of company sales in fiscal 2026 and grew 6%, which is roughly twice the rate of the company as a whole — the clearest structural shift in the channel mix, and one that carries a cost, because the retailer's margin requirement in digital is higher than in a supermarket aisle.

Scale is the moat, and it is a real one. P&G sells in about 180 countries and territories with on-the-ground operations in roughly 65. North America alone is 51% of net sales and the company holds a share position in Bounty paper towel of nearly 40% and in Charmin toilet paper of more than 25% — positions that no private label programme has been able to dislodge in four decades. Its manufacturing base is dense enough to absorb commodity shocks, and its advertising budget of $10.2 billion is larger than the entire revenue of most of its competitors.

But the geographic mix is also the source of the growth problem. More than half of sales come from outside the United States. The largest international markets — Greater China, the United Kingdom, Canada, Japan and Germany — together are about 21% of net sales. Within that, Greater China is 7% of the company and the single most volatile piece of it: the region that produced a mid-teens decline in oral care volume in FY2026 while producing double-digit organic growth in baby care over six consecutive quarters. The company's own framing is that Focus Markets grew organic sales "modestly" and that Enterprise Markets grew 4%, led by Latin America at 6%. Read plainly, the developed markets that generate most of the profit are growing at roughly the rate of inflation, and the growth is coming from smaller, lower-margin, more volatile geographies.

03 — The financial recordFive years, and the moment the arithmetic stopped working

P&G's five-year record is genuinely good on the measures most investors track. Net sales went from $80.2 billion in FY2022 to $87.0 billion in FY2026. Diluted earnings per share went from $5.81 to $6.62. Core EPS went from $5.81 to $6.89. Operating cash flow went from $16.7 billion to $19.6 billion. The dividend went from $3.52 a share to $4.26. On a total-return basis, however, the last five years have been mediocre: 3.85% annualised, against 8.14% over ten years. The operating record and the shareholder outcome have diverged, and the reason is the multiple.

The shape of the five years is what matters. FY2022 through FY2024 were the inflation years, and P&G handled them well. Organic sales grew 7%, 7% and 4% in those three years — the best stretch of pricing-led growth in the company's modern history — and gross margin expanded from 47.4% to 51.4% as commodity costs normalised. FY2025 was the peak: operating margin of 24.3%, net margin of 19.1%, core EPS up 3.6%. FY2026 is where the arithmetic changed. Organic growth fell to 1%, operating margin fell back to 22.7%, and net margin fell to 18.5%.

One accounting item distorts the visual. FY2024 operating income of $18.5 billion includes a $1.3 billion before-tax, $1.0 billion after-tax non-cash impairment of the Gillette indefinite-lived intangible asset, taken because of a higher discount rate, a weaker dollar translation of several currencies, and the effect of the restructuring programme. Without it, FY2024 operating margin would have been roughly 23.5% rather than 22.0%, and the FY2025 step-up would look much smaller than the chart implies. The Gillette intangible remains the single largest asset on the balance sheet and remains susceptible to further impairment; management disclosed in the FY2026 ten-K that fair value continues to exceed carrying value but that the headroom is not unlimited.

The quarterly path shows the same story at higher resolution. Reported growth was negative or flat through the first four quarters of the window and then improved, which is what management means when it says the company "moved from up one point in the first half of the year to two points in the second half." The problem with reading that as an inflection is the base. The March 2025 quarter — Q3 of fiscal 2025 — was $19.8 billion, the weakest print in the window, which is why the March 2026 quarter appears to grow 7%. It did not. Organic sales in that quarter rose roughly 2%, and the reported figure is dominated by currency translation against a depressed comparison.

The final quarter of the fiscal year is the one to sit with. Net sales of $21.2 billion were up 2%, but organic sales were unchanged, and the composition of the 2% was one point of foreign exchange and one point of rounding. Reported gross margin fell 60 basis points and core gross margin was flat. Reported SG&A rose 160 basis points as a percentage of sales; core and currency-neutral SG&A each rose 130 basis points, of which 410 basis points was reinvestment, primarily marketing, against 300 basis points of productivity savings. Reported operating margin fell 220 basis points; excluding 90 basis points of non-core restructuring charges, core operating margin fell 130 basis points. Reported diluted EPS fell 15% and core EPS fell 3%. This is what the end of a pricing cycle looks like on an income statement.

Two features of that table deserve emphasis. The first is that net earnings attributable to P&G has been essentially flat for two years — $16.0 billion in FY2025 and $16.0 billion in FY2026 — while reported sales grew 3%. All of the FY2026 earnings growth came from a lower share count, not from the business. Diluted EPS rose 2% because the share count fell, and the share count fell because the company bought back $5.0 billion of stock, funded partly with debt. The second is that capital expenditure has risen 39% over three years, from $3.2 billion to $4.4 billion, without any corresponding increase in unit volume. P&G is spending more to stand still.

04 — Segment deep diveBeauty: the growth engine, and the margin bill for running it

Beauty is P&G's best growth story and its worst margin story, and both facts have the same cause. Segment net sales rose 7% to $16.0 billion, the fastest of the five segments. Unit volume rose 4%, the only positive volume print in the company. Organic sales rose 5%. And segment net earnings fell 2% to $2.7 billion, because net margin declined 140 basis points to 16.7% — the lowest of any segment and a 140-basis-point give-back in a single year.

The mechanics are worth walking through because they generalise. Beauty's 7% net sales growth breaks into 4% volume, 2% foreign exchange and 1% pricing. That is a healthy mix: real units, not price. But the units are being sold at a mix that dilutes gross margin. The company attributes the 100-basis-point gross margin decline in Beauty to "unfavourable product mix and higher commodity costs, partially offset by productivity savings," and then separately notes that Skin Care net sales rose mid-single digits "driven by positive impacts of favorable product mix (due primarily to the increase of the super-premium SK-II brand, which has higher than category-average selling prices)."

That looks like a contradiction until you follow it through. SK-II carries a higher selling price than the category average, so it lifts revenue per unit — that is the "favourable product mix" at the revenue line. But SK-II also carries a much higher marketing and channel cost, particularly in Greater China, where the brand is distributed through prestige counters and department stores and now increasingly through Douyin and other social channels that take a larger cut. The gross margin on the incremental SK-II unit is higher; the operating margin, after the marketing required to sell it, is lower. Hence a segment that grew revenue 7% and volume 4% while its net margin fell 140 basis points.

The share data is the part that should worry a long-term holder. P&G's Beauty segment lost 0.3 points of global value share in FY2026. Within it, hair care lost 0.5 points and skin care lost 0.6 points, against a 0.2-point gain in personal care. The company grew the category and lost position within it — the definition of a business growing with the market rather than against it. Management's own framing is that global value and volume share trends improved in the second half and exited the year "roughly flat," and that 26 of the top 50 category/country combinations held or grew share. That is a fair statement and a low bar.

The bull argument on Beauty is straightforward: it is the only segment with genuine volume growth, the only one where innovation is visibly producing new consumption rather than redistributing existing consumption, and the only one with a credible path to a higher multiple if the margin troughs. Pantene in Germany is the case study the company puts forward — a reinvention of the brand's communication through social and influencer channels that produced a four-fold increase in influencer-generated content, a tripling of reach, 14% value sales growth and half a point of share. The bear argument is that a segment growing volume at the cost of 140 basis points of margin is not compounding anything; it is trading profitability for revenue in a category where the trade may not be reversible.

05 — Segment deep diveGrooming: the highest margin, the smallest base, and shrinking units

Grooming is the smallest of the five segments at $6.9 billion of net sales — 8% of the company — and the most profitable, with a segment net margin of 22.1%. It is also the segment with the clearest structural problem. Unit volume fell 1% in FY2026 after falling 1% in FY2025. Net sales rose 4% only because 3 points came from foreign exchange and 2 points from price. Organic sales rose 1%. Global segment share fell 0.4 points.

The Grooming segment is dominated by Gillette, and the Gillette business is the single most important brand franchise in P&G's portfolio in terms of margin, if not in terms of revenue. It is also the franchise carrying the largest accounting risk: the Gillette indefinite-lived intangible asset, recognised on the 2005 acquisition, was written down by $1.3 billion before tax in FY2024 and remains the largest single asset on the balance sheet. Management's FY2026 disclosure is that fair value continues to exceed carrying value. But the valuation of that asset depends on forecast net sales growth, royalty rate and discount rate, and the discount rate has been rising.

The volume decline has two components. The first is Asia Pacific, where Grooming organic sales fell high single digits; management attributes this to competitive activity and distribution losses. The second is a slow structural shift in the developed markets, where the shaving occasion itself is under pressure. This is the category where the GLP-1 question is most often asked, and the honest answer is that the evidence is mixed: the direct effect on shaving is probably small, but the broader consumer shift toward fewer, more deliberate personal-care purchases is real and is visible in the unit data.

Grooming's importance to the investment case is disproportionate to its size. Because it carries the highest margin, every point of Grooming volume decline costs the consolidated operating margin more than a point of Fabric & Home Care decline would. And because it is the segment most exposed to the Gillette intangible, it is the segment most likely to produce a large non-cash charge in a stress scenario. We do not forecast an impairment. We do note that the last one arrived without much warning.

06 — Segment deep diveHealth Care: 4% sales growth, 2% less product, and a Greater China problem

Health Care grew net sales 4% to $12.5 billion — the same reported rate as Grooming — and did it while shipping 2% fewer units. The composition was 3 points of foreign exchange, 2 points of price and 1 point of favourable mix, against a 2-point volume decline. Organic sales rose 1%. Net earnings fell 1% to $2.4 billion and net margin narrowed 100 basis points to 19.3%.

Health Care is the one segment where P&G gained global share: the segment share rose 0.4 points, personal health care rose 0.5 points and oral care held flat. That is a genuinely better outcome than the other four segments, and it comes from the same place the growth does — premiumisation. Oral care net sales rose low single digits on favourable product mix, driven by "growth of premium paste and power brushes, which have higher than category-average selling prices," against a volume decline. Personal health care rose mid-single digits on pricing, led by North America, against a volume decline caused by "lower average incidence of cough and cold."

The volume decline is the story. Oral care unit volume fell on a decline in Greater China — attributed to "market contraction and competitive activity" — and North America, attributed to competitive activity. The organic sales line in oral care was unchanged, with a low single-digit increase in Europe entirely offset by a mid-teens decrease in Greater China. A mid-teens decline in the largest category of a $12.5 billion segment, in the region that is both the most competitive and the most strategically important, is not a rounding error.

Against that, the segment has the most credible acquisition story in the portfolio. On 4 August 2026 — five weeks after the fiscal year closed — P&G agreed to acquire Thorne, a science-backed premium supplement brand in the vitamins, minerals and supplements category, for $3.8 billion in cash, from a fund managed by L Catterton. Management expects the transaction to close in the second quarter of fiscal 2027, subject to regulatory approval. Thorne is not a scale business — it is a practitioner-channel brand — but it is a genuine adjacency: the supplements category is growing at a rate P&G's own categories are not, and it sells to a consumer who is already buying health care.

The Health Care segment therefore presents the cleanest version of the P&G dilemma. Share is being gained, premiumisation is working, the acquisition strategy is rational, and the volume line is negative. The company is defending and extending a franchise in a category where the number of units consumed is not growing, by charging more per unit and buying adjacent businesses. That can work for a long time. It cannot work forever.

07 — Segment deep diveFabric & Home Care: the largest segment, and the one where nothing moved

Fabric & Home Care is the biggest thing P&G owns: $30.3 billion of net sales, 35% of the company, and home to Tide, Ariel, Downy, Lenor, Bounce, Gain, Era, Bounty, Charmin, Puffs and Febreze. It is also the segment where the volume line is most instructive, because it is the one segment where unit volume was exactly unchanged — not down, not up, simply flat — and the segment still reported 2% net sales growth.

The 2% came from 1 point of foreign exchange and 1 point of pricing. Organic sales rose 1%. Net earnings fell 4% to $5.6 billion and net margin narrowed 110 basis points to 18.6%. Global segment share was unchanged, which in a segment this size is a genuinely respectable outcome — it means P&G held its position in detergent and paper across every geography simultaneously. Home care share rose 0.3 points. Fabric care held.

The gross margin decline of 140 basis points in this segment is the second-largest of the five, and management attributes it to "unfavourable product mix and higher commodity costs, partially offset by productivity savings." Fabric care is the most commodity-exposed business in the portfolio: resin, pulp, surfactants, enzymes, zeolites, sodium sulphate and the energy to run continuous process plants. When input costs move, this segment absorbs it first. That is also why it was the segment that produced the largest margin expansion in the FY2022-to-FY2024 period when costs fell.

The strategic question in Fabric & Home Care is whether the category has any volume growth left in it at all. Household penetration of laundry detergent in the developed markets is close to saturation; the growth comes from premiumisation within the category (unit-dose formats, premium scent, concentrated formulas), from emerging-market penetration, and from adjacent product forms. P&G's answer is the first and third: Gain and Tide in unit-dose formats, Downy and Lenor in scent boosters, and the home-care line extending from cleaning into air and fabric freshening. That is a sensible strategy. It is also a strategy that grows revenue without growing units, which is precisely what the FY2026 numbers show.

08 — Segment deep diveBaby, Feminine & Family Care: the only segment that shrank organically

Baby, Feminine & Family Care is the only one of the five segments where organic sales declined. Net sales rose 1% to $20.4 billion — entirely from 2 points of foreign exchange — while unit volume fell 1% and organic sales fell 1%. Net earnings fell 2% to $3.9 billion, net margin narrowed 50 basis points to 19.3%, and global segment share fell 0.2 points. In a company that is otherwise holding its ground, this is the segment that is losing it.

The segment contains three distinct businesses with three different problems. Baby Care, dominated by Pampers, is the good news: net sales rose low single digits on a volume increase, with a 20% organic increase in Greater China and a mid-single-digit increase in IMEA offsetting a low-single-digit decline in North America. Global baby care share rose 0.3 points. The Greater China baby business is, by management's own account, the single best execution story in the company: double-digit organic growth in each of the past six quarters and nearly five points of value share gained, on the back of an insight-driven innovation — a diaper using silk materials to deliver skin comfort — that translated a Chinese parent's demand for "only the best" into a product and a package that communicate superiority at first touch.

Feminine Care is the middle case. Net sales rose low single digits on favourable FX, favourable geographic mix and higher pricing in North America, against a volume decline driven by IMEA and Europe on competitive activity and by Greater China on market contraction. Organic sales were unchanged, with low single-digit growth in North America offset by a high single-digit decline in IMEA and a low single-digit decline in Europe. Market share fell 0.2 points. This is a business being held, not grown.

Family Care is the problem. It is predominantly a North American business — Bounty and Charmin — and net sales fell low single digits on lower pricing, which is a rare thing to see in a P&G segment, plus a volume decline on competitive activity. Organic sales fell low single digits and North America's share of the family care category fell 0.7 points. Management's explanation is "merchandising investments," which is corporate language for price promotion in response to competition.

It is worth being fair about the magnitude. Seven-tenths of a point of share in a single category in a single year is not a collapse, and Family Care is a relatively small piece of a $20.4 billion segment. But direction matters more than level in consumer staples, and the direction here is negative in the segment with the least room to recover. Birth rates in the developed markets are falling, which caps the baby business; household formation is slowing, which caps family care; and feminine care is a category where private label has been gaining steadily for a decade. The segment's best growth market is Greater China, which is 7% of the company and the most competitive region P&G operates in.

09 — The growth engineVolume, price, mix and currency, decomposed

P&G discloses a sales-driver table in every ten-K that decomposes reported net sales growth into unit volume, foreign exchange, price, mix and "other." It is the single most useful table in the filing, and it is worth reading carefully, because it is where the difference between a growing company and a re-priced one becomes visible.

Read the total row. Reported net sales growth of 3% is composed of 2 points of currency, 1 point of price, and nothing from volume and nothing from mix. Organic growth — the company's preferred measure, which excludes currency and acquisitions — is 1%, entirely from price. There is no volume contribution anywhere in the consolidated table.

The segment rows show the same pattern with more texture. Health Care took 2% of price, 1% of favourable mix and 3% of currency, and shipped 2% fewer units. Grooming took 2% of price and 3% of currency and shipped 1% fewer. Fabric & Home Care shipped exactly the same number of units and took 1% of price. Only Beauty grew units, and only Beauty has a volume-driven story.

This is what the end of a pricing cycle looks like. From FY2022 to FY2024, P&G took 3% to 5% of price a year and held volume flat or better — the classic inflation pass-through that staples investors reward, because it demonstrates pricing power without demand destruction. By FY2025 the price contribution had fallen to about 2%. In FY2026 it is 1%. And unlike the earlier years, the volume line has not recovered as pricing has slowed: it was zero in FY2025 and zero in FY2026.

The bull reading of this is that a company which raised prices 3-5% a year for four years inevitably gives some of it back, and that FY2026's 1% of price with flat volume is the trough. Management's own framing supports it: organic growth improved from one point in the first half to two points in the second half, market share trends improved in the back half, and the company expects the "sequential progress" to continue. The bear reading is that flat volume at 1% price is not a trough but a destination — the steady state of a mature portfolio in saturated categories — and that the FY2027 guidance of 1% to 3% organic growth, with a 30-to-50 basis point headwind from brand and product-form discontinuations, is consistent with the second reading as much as the first.

10 — Greater ChinaThe SK-II reset worked. It also cost the company its skin-care share.

Greater China is 7% of P&G's net sales — roughly $6 billion — and it has been the most disruptive variable in the company's results for four years. The story is worth telling properly because it is the clearest available test of whether P&G can execute a turnaround in a difficult market.

The problem began in FY2024. SK-II, P&G's super-premium skin-care brand and the anchor of its prestige beauty position in Asia, lost its footing in China. The causes were a combination of consumer nationalism directed at Japanese brands, a sharp deterioration in Chinese consumer confidence, the migration of beauty purchasing from department-store counters to Douyin and other social commerce platforms, and a competitive response from domestic Chinese brands who understood those channels better. SK-II sales in Greater China fell by roughly a third. The segment's skin care share went with it, and Beauty's net margin, which had been the segment's most stable number, began to fall.

The response, which management calls "the fundamental reinvention of the China model," was a rebuild of the go-to-market structure, the portfolio, the communication model and the innovation pipeline. Chief financial officer Andre Schulten described it on the FY2026 third-quarter call as work that is "starting and continuing to pay dividends," and the numbers support him. In the March 2026 quarter, SK-II grew 18% globally and 13% in Greater China, the third consecutive quarter of progress. Greater China organic sales for the full fiscal year rose 4%, against a company-wide organic rate of 1%. Greater China baby care delivered double-digit organic growth for the sixth consecutive quarter and gained nearly five points of value share.

The costs of the reset are visible in the share data. P&G's skin care category lost 0.6 points of global value share in FY2026 and its hair care category lost 0.5 points, while personal care gained 0.2 points. Oral care organic sales were unchanged for the year, with a mid-teens decline in Greater China offsetting growth everywhere else. The company recovered the growth rate and did not recover the share, which is the normal signature of a recovery bought with price and marketing investment rather than with structural advantage.

For the investment case, the practical implication is that Greater China should be modelled as a source of volatility rather than as a growth engine. It contributed 4% organic growth in FY2026, which sounds like a tailwind, but it did so off a base that had been substantially reset and it did so while diluting segment margins. A 7% revenue exposure that swings by twenty points year-on-year, in the company's most competitive region, is not something a 21-times multiple should be paying much for.

11 — Margins and productivityFive segments, five margin declines, and a productivity programme carrying the whole thing

The single most striking fact in P&G's FY2026 disclosure is not that margin fell. It is that margin fell in every segment. Beauty gave up 140 basis points of net margin, Grooming 160, Health Care 100, Fabric & Home Care 110 and Baby, Feminine & Family Care 50. There is no segment where mix, pricing or productivity was sufficient to offset the combination of input costs, unfavourable mix and rising marketing spend.

The pattern is consistent enough to be structural rather than incidental. In every segment the disclosure names the same two drivers: gross margin decline from unfavourable product mix and higher commodity costs, and SG&A increase from higher marketing spending. Productivity savings appear in every segment as a partial offset, and in no segment as a full one.

The fourth-quarter bridge makes the mechanics precise, and it is worth reproducing because it is the clearest statement of the trade P&G is making. Q4 core gross margin was flat. Within it, productivity savings added 160 basis points and a net tariff benefit added 40 basis points. Those were offset by 120 basis points of unfavourable product mix, 70 basis points of product and package reinvestment, and 40 basis points of higher commodity costs. On the SG&A line, 410 basis points of reinvestment — primarily marketing — was offset by 300 basis points of productivity savings in marketing and overhead. Net: core operating margin down 130 basis points.

This is where the restructuring programme becomes important. In June 2025 P&G announced a portfolio and productivity plan to "streamline its portfolio and organization to improve its cost structure and invest in growth." The FY2026 ten-K quantifies it at approximately $1.5 to $2.0 billion of before-tax restructuring costs over a two-year period, including the ongoing restructuring programme, with more than half incurred in fiscal 2026 and the remainder expected in fiscal 2027. The headcount element is a reduction of up to 7,000 non-manufacturing overhead positions by the end of fiscal 2027. Total employment fell 4% in FY2026 to approximately 104,000.

Seven thousand roles out of a non-manufacturing population that we estimate at roughly 35,000 is a fifth of the overhead base. If the average fully-loaded cost of an overhead position is around $120,000, the annualised saving is roughly $840 million — about 0.9% of operating cost, or roughly $0.29 per share after tax. That is a meaningful number against FY2027 core EPS guidance of $6.89 to $7.11, and it is the single largest controllable lever management has. The question is whether it will show up in margin or be reinvested, as the past three years of productivity have been.

Our expectation is that most of it will be reinvested, and the evidence is in the advertising line. P&G's restructuring savings have been recycled into marketing for three years running, and management's stated logic is that superiority requires investment. That is a defensible strategy — brand equity is the asset that produces the next decade of pricing power — but it means the FY2027 restructuring charge should be modelled as a cost that improves the competitive position rather than as one that improves the reported margin.

12 — Quality of earningsThree numbers that do not appear in the press release

P&G's earnings are high quality by any reasonable standard. There is no channel stuffing to speak of, no aggressive revenue recognition, no capitalised cost of any significance, and operating cash flow of $19.6 billion exceeds net earnings of $16.1 billion. Free cash flow conversion is above 100%. The auditor, Deloitte & Touche, has served since 1890 and signed an unqualified opinion in August 2026. This is not a company where the earnings need to be reconstructed.

But three items in the FY2026 numbers deserve to be separated from the operating result, because they flatter it or obscure it, and none of them appears in the headline press release.

First, the Glad joint venture dissolution. In January 2026 the Glad joint venture agreement between P&G and The Clorox Company expired. Clorox purchased P&G's minority interest at fair market value for $476 million, the transaction was accounted for as a dissolution, and P&G recorded an after-tax gain of $261 million. That gain sits in the Corporate line, which reported a net loss of only $23 million for the year against a $527 million loss in FY2025 — a $504 million swing that is almost entirely the Glad gain plus lower restructuring. Core EPS excludes the Glad gain, which is why core EPS of $6.89 is $0.27 above GAAP diluted EPS of $6.62. An investor reading only the GAAP line would conclude that earnings were flat; the reality is that operating income fell 3%.

Second, the tariff recovery. On 20 February 2026 the United States Supreme Court ruled that the tariffs imposed under the International Emergency Economic Powers Act were invalid. P&G had previously paid approximately $200 million in IEEPA tariffs and disclosed that the amount "may be recoverable." In the quarter ended 30 June 2026 the company recognised recovery of half of that amount — roughly $100 million before tax — in its consolidated financial statements. The remaining half is not yet recognised. This is a genuine cash benefit, but it is a one-off reversal of a cost that was itself a one-off, and it contributed to the 40 basis points of net tariff benefit in Q4 core gross margin.

Third, and most importantly, the advertising line. P&G's advertising expense was $10.2 billion in FY2026, against $9.2 billion in FY2025 and $9.6 billion in FY2024. Research and development expense was flat at $2.1 billion. So the company increased the amount it spends telling consumers about its products by $1.0 billion, an 11% increase, while increasing the amount it spends inventing new ones by nothing at all — and while organic sales growth fell from 2% to 1%.

One further quality consideration deserves mention. P&G funds its buyback partly with debt. In FY2026 the company spent $5.0 billion on treasury stock purchases and paid $10.2 billion of dividends — $15.2 billion of capital return against $15.1 billion of free cash flow, a payout of just over 100%. Total debt rose from $33.7 billion in FY2024 to $35.0 billion in FY2026, with long-term debt falling from $25.0 billion to $22.8 billion and short-term borrowings rising. The ten-K states explicitly that the share repurchases were "financed through a combination of operating cash flows and issuance of debt." This is not dangerous — debt is 1.4 times EBITDA and interest coverage is 24.6 times — but it means the share count reduction that produced all of FY2026's EPS growth is being bought with borrowed money, at a moment when the company's own dividend yields less than the risk-free rate.

Net-net, we would describe P&G's FY2026 earnings as high-quality cash flows attached to a slightly overstated headline. The $261 million Glad gain, the $100 million tariff recovery and the $5.0 billion debt-funded buyback all served to make a year of 3% operating income decline look like a year of flat-to-modest growth. Core EPS of $6.89, up 1%, is the cleanest available measure of what actually happened, and even that includes the benefit of the lower share count.

13 — Capital allocationSeventy years of dividend increases, and the arithmetic behind them

P&G's dividend record is the most important single fact about the company as an investment. In April 2026 the board raised the quarterly dividend for the seventieth consecutive year, extending a streak that no other company of comparable size has matched. The company has paid a dividend every year since its incorporation in 1890 — 136 consecutive years. In FY2026 it paid $10.2 billion of dividends and repurchased $5.0 billion of stock, returning over $15 billion to shareholders.

The arithmetic of that streak is where it gets interesting. Dividends paid rose from $9.9 billion in FY2025 to $10.2 billion in FY2026, an increase of 3.6%. Free cash flow rose from $14.0 billion to $15.1 billion. So the dividend was covered 1.48 times by free cash flow — comfortable. But total capital return, including the buyback, was $15.2 billion against $15.1 billion of free cash flow, a payout ratio of 101%. The buyback is the part that is not covered, and it is funded with debt.

Whether that is a problem depends on the alternative. P&G's weighted average cost of capital is approximately 5.9% on the company's own estimate basis, and its long-term debt carries investment-grade coupons well below that. Buying back stock at a 4.5% free cash flow yield with debt costing, say, 4.5% to 5.0% is roughly value-neutral before the tax shield and modestly accretive after it. The buyback is not destroying value. It is also not creating much, and it is the entire source of the 2% EPS growth the company reported for the year.

The forward picture is set by guidance. For FY2027 P&G expects to pay approximately $10 billion of dividends and to repurchase approximately $5 billion of stock, and guides adjusted free cash flow productivity of 85% to 90% — down from 100% in FY2026. That is a deliberate step down, and it reflects the restructuring cash costs, the Thorne acquisition, and a higher capital expenditure budget. The company is telling investors that the cash return will exceed free cash flow by more than it did in FY2026, which means more borrowing.

For an income investor, the relevant question is whether a 2.95% dividend yield that grows at 3% to 4% a year is adequate compensation for the risk. The answer depends on the alternative, and the alternative is now 5.31%. To justify the shares on a dividend-discount basis at a 7.0% cost of equity, P&G needs to grow the dividend at 4.0% in perpetuity — roughly double the rate of volume growth it is currently achieving, and above the rate at which its own earnings are growing. That is not impossible; it is simply not free.

14 — Balance sheet & financingA fortress with a mortgage on it

P&G's balance sheet is strong by any conventional measure and slightly odd by a few unconventional ones. At 30 June 2026 the company held $9.9 billion of cash and equivalents against $35.0 billion of total debt, for a net debt position of $25.1 billion. That is 1.39 times EBITDA and 2.31 times free cash flow. Interest coverage is 24.6 times. Total shareholders' equity is $54.3 billion and return on equity is 30.3%.

The oddities are in the liquidity ratios. P&G's current ratio is 0.68 and its quick ratio is 0.41. Current liabilities of $38.7 billion exceed current assets of $26.2 billion by $12.5 billion. For a manufacturer with a working capital cycle, that would be alarming. For P&G it is a deliberate capital structure: the company funds itself with short-term commercial paper against long-term operating cash flow, keeps minimal inventory and receivables relative to payables, and relies on the fact that its cash generation is about as predictable as any corporate cash flow in the world. It has run negative working capital for years.

The composition of the debt has shifted. Long-term debt fell from $25.0 billion to $22.8 billion while total debt rose, meaning short-term borrowings increased. Total debt went from $33.7 billion in FY2024 to $36.5 billion in FY2025 and $35.0 billion in FY2026. The company refinanced opportunistically and issued notes during FY2026 partly to fund the buyback.

The largest single asset on the balance sheet is not a factory or a receivable. It is the Gillette indefinite-lived intangible, recognised on the 2005 acquisition of The Gillette Company and carried at a value that has already been written down once — by $1.3 billion before tax and $1.0 billion after tax in FY2024 — because of a higher discount rate, weaker foreign currency translation and the effects of the restructuring programme. Management's FY2026 disclosure is that fair value continues to exceed carrying value, but the valuation rests on forecast net sales growth, a royalty rate and a discount rate, and the discount rate has been rising with the ten-year.

We are not forecasting a further impairment. We are noting that the asset is sensitive to two variables that are currently moving in the wrong direction — the discount rate and the sales growth rate of the Grooming segment, which shipped 1% fewer units in FY2026 and lost 0.4 points of global share. A second write-down would be non-cash and would not affect free cash flow. It would, however, remove book equity, push the debt-to-equity ratio up from its current 0.64, and force a conversation about what the Gillette franchise is actually worth.

Two further balance-sheet items bear on FY2027. The first is the Thorne acquisition, $3.8 billion in cash, expected to close in the second quarter of fiscal 2027, which will consume roughly a quarter of annual free cash flow and add goodwill to the asset base. The second is the restructuring programme, which carries $1.5 to $2.0 billion of before-tax cash costs over two years, of which the remainder lands in FY2027. Both are already reflected in the 85% to 90% adjusted free cash flow productivity guidance.

15 — Private labelThe retailer is now the competitor, and the shelf is the battleground

P&G's own risk factors name it plainly: "In many of the markets and industry segments in which we sell our products, we compete against other branded products as well as retailers' private-label brands." That sentence has appeared in the ten-K for years and has always been true. What has changed is the rate at which it is becoming consequential.

Private label's share of the consumer staples categories is now in the low twenties and rising. Independent tracking through 2026 puts store-brand share of staples at roughly 22.5% with improving momentum, and the direction is what matters: private label has historically gained share during inflationary periods and then given some of it back when inflation subsides. This cycle, the give-back has not happened. Several structural changes explain why. Retailers have invested in their own-brand quality to the point where the sensory gap in detergent, paper and personal care has narrowed to the point of irrelevance for a large share of shoppers. Retail media networks have given retailers both the data and the margin to promote their own brands profitably. And discount formats — hard discounters in Europe, club and value channels in the United States — have grown faster than the traditional supermarket, and those formats are structurally underweighted in branded goods.

P&G's response is to compete on the vectors where private label cannot follow. Management frames this as "superiority across five key vectors — product performance, packaging, brand communication, retail execution and value" — and the portfolio is explicitly positioned in categories "where performance plays a significant role in the consumer's choice of brands." That is a real defence. A private-label diaper does not deliver the skin-comfort innovation that grew Greater China baby care at double digits for six quarters. A private-label razor does not carry the Gillette blade architecture. Where performance is demonstrable and testable, the branded premium holds.

The vulnerability is in the categories where performance is not demonstrable — where the product is a commodity with a brand attached. Toilet paper and paper towel are the clearest examples. The functional difference between Charmin and a good store brand is small and easy to test; the price difference is 30% to 40%. That is why Family Care is where the share loss appeared, and why management responded with price investment rather than with innovation. There is no innovation available that a retailer cannot match within eighteen months.

The second-order effect is on the retailer relationship, and here P&G is doing something genuinely interesting. The company's third stated external change is the transformation of the retail landscape — agentic commerce, quick commerce, social commerce, and the convergence of retailers into media platforms and media platforms into retailers. Its response is "holistic partnerships with retailers," which in practice means joint business planning, shared data and co-developed category strategies. This is the right answer to a world where the retailer controls the shelf, the search result and increasingly the agent that makes the purchase decision. It is also a strategy that trades margin for position: joint plans with retailers generally involve funding the retailer's growth.

Our assessment is that private label is a persistent one-to-two-point annual drag on P&G's volume growth in the mature categories, and that it is largely offset by premiumisation and emerging-market penetration in the others. That is exactly what the FY2026 volume line of zero looks like when you decompose it. It is not a crisis. It is a permanent tax on the growth rate, and it is one of the reasons we do not expect P&G to return to the 4% to 7% organic growth of FY2022 to FY2024.

16 — The competitive mapP&G is the best business in a category that is no longer growing

The consumer staples universe divides into three groups. There are the household and personal products companies that compete with P&G directly — Colgate-Palmolive, Unilever, Henkel, Reckitt, Kimberly-Clark, Church & Dwight. There are the beverage and food companies that share the staples label but not the categories — Coca-Cola, PepsiCo, Mondelez, General Mills. And there are the beauty companies, which compete with P&G's Beauty segment but operate on entirely different economics — L'Oréal, Estée Lauder, the Japanese and Korean prestige houses.

On the multiple, P&G sits mid-pack: 22.0 times trailing earnings, against 34.0 times for Colgate-Palmolive, 30.7 times for Church & Dwight, 26.0 times for Coca-Cola, 16.5 times for PepsiCo, 16.4 times for Kimberly-Clark and 12.1 times for Unilever. Estée Lauder trades at 186 times on a collapsed earnings base and is not a meaningful comparator.

The dispersion in that table is the most informative thing in this section. Coca-Cola returned 33% over the last twelve months and P&G returned 0.05%. PepsiCo and Kimberly-Clark — the two peers closest to P&G in category structure — returned negative 7.7% and negative 17.9%. Unilever, the closest thing to a direct comparable in household and personal care, returned negative 5.9%. The market is not repricing staples as a sector. It is repricing the sub-sector P&G belongs to: mature household and personal products with flat volume, and it is paying up for beverage franchises and for anything with a plausible growth narrative.

Within P&G's own categories, the competitive dynamics differ by segment. In Fabric & Home Care the principal global competitors are Henkel and Unilever, with regional players and private label taking the rest; the category is consolidated, P&G is the leader, and the competition is mostly on price and promotional intensity. In Baby Care the principal competitor is Kimberly-Clark through Huggies, with Japanese and increasingly Chinese brands in Asia; the category is a duopoly in the developed markets and a free-for-all in the emerging ones. In Grooming the competitor is Edgewell and a long tail; Gillette's position is dominant and slowly eroding. In Oral Care the competitor is Colgate, and the category is a genuine duopoly with roughly even shares. In Beauty, P&G is a mid-sized player against L'Oréal, Estée Lauder, Shiseido and a fast-growing cohort of Chinese and Korean brands, and it is the only segment where P&G is not the leader in most of the categories it competes in.

17 — Demand structureBirth rates, household formation, GLP-1 and the ceiling on volume

P&G's volume problem has a demographic component that no amount of marketing can fix. The company's categories are consumed at a rate determined by the number of people, the number of households, and the frequency of the underlying activities — laundering clothes, brushing teeth, changing diapers, shaving, cleaning a bathroom. All three of those drivers are flat to declining in the developed markets that generate most of P&G's profit.

Population growth in North America and Europe is below one per cent a year and is concentrated in age cohorts that consume less of P&G's portfolio. Birth rates in both regions have fallen to levels that imply long-run population decline without immigration, which directly caps the Baby Care and Family Care businesses — together roughly $20 billion of revenue. Household formation has slowed in the United States as housing costs have risen, which reduces the number of new households starting from zero and therefore reduces the initial purchase of every category P&G sells.

The emerging markets tell the opposite story, which is why they are the growth engine, but they carry their own constraints. Greater China, Latin America, Asia Pacific and IMEA together are roughly 26% of net sales and are growing organic sales at 4% to 6% — three to six times the rate of the developed markets. But those markets are more competitive, more price-sensitive, more exposed to currency translation, and structurally lower-margin. The Latin America business grew 6% organic in FY2026 and is a genuine bright spot; it is also a region where P&G has previously had to exit countries entirely, as it did in Argentina in FY2025 at a cost of $1.2 billion after tax.

There is also a substitution effect working in P&G's favour, and it is underappreciated. As household budgets have been squeezed by five years of cumulative inflation, consumers have traded down within categories rather than out of them — buying smaller pack sizes, buying mid-tier rather than premium, buying at discount channels. P&G's explicit response is to offer "products at the right sizes and price points, while continuing to deliver the performance, quality and value consumers expect from P&G brands across every value tier." That is a revenue-defensive strategy: it protects units at the cost of revenue per unit. It shows up in the numbers as flat volume with negative mix, which is precisely what FY2026 reported.

The long-run consequence is a company whose volume growth is structurally capped at roughly population growth plus penetration gains in the emerging markets, minus private-label share loss in the developed ones. That nets to something between zero and two per cent, which is exactly where P&G has been for two years. Any investment case that assumes a return to the 4% to 7% organic growth of FY2022 to FY2024 needs a specific mechanism for volume — and the company has not yet articulated one.

18 — CostsTariffs, currencies and the $0.56 per share that FY2027 has to absorb

P&G guided FY2027 core EPS growth of "in-line to +3%" on a FY2026 base of $6.89, a range of $6.89 to $7.11 with a midpoint of $7.00. Buried in that guidance is the most useful disclosure in the release: the company quantified the total headwind at $0.56 per share, roughly an eight-point drag on core EPS growth. Of that, about $0.43 is higher raw materials, energy and transportation costs — approximately $1.0 billion after tax — with $0.06 from higher net interest expense, $0.06 from lower non-operating income and $0.02 from unfavourable foreign exchange.

The bridge is instructive because it tells you what management actually believes. Excluding the quantified headwinds, underlying core EPS growth would be roughly 10%. That is a strong number, and it implies management expects productivity, pricing, mix and the buyback to combine to produce about $0.69 of EPS growth before costs. The guidance of $7.00 is therefore not a forecast of a slow year; it is a forecast of a strong year in which the gains are spent on inputs before they reach the shareholder.

The tariff picture has improved in a way that is genuinely unusual. On 20 February 2026 the United States Supreme Court ruled that the tariffs imposed under the International Emergency Economic Powers Act were invalid. P&G had previously paid approximately $200 million in IEEPA tariffs, disclosed that the amount "may be recoverable," and in the June 2026 quarter recognised recovery of half of it — about $100 million before tax. The remaining half is not yet recognised. The company's estimate of its FY2026 tariff cost had been in the region of $500 million to $1 billion before tax; the Supreme Court ruling removes the legal basis for a substantial part of it.

The resolution is not unambiguously good news, and the fourth-quarter numbers show why. Q4 core gross margin included a positive 40 basis points of "net tariff benefit from recognized recoveries and higher costs" — a line that nets a one-time recovery against ongoing cost inflation and tells you the company is no longer treating tariffs as a discrete headwind. Section 232 tariffs on steel and aluminium, Section 301 tariffs on Chinese imports and the general uncertainty around trade policy all remain. P&G manufactures in roughly 65 countries and sells in 180, which makes it simultaneously exposed to tariffs on inputs and to retaliatory tariffs on its own exports.

Currency is the third variable. FY2026 net sales benefited by 2 points from foreign exchange, the single largest contributor to the reported growth rate. That is a translation effect on a company that earns more than half its revenue outside the United States, and it reverses as easily as it arrived. Management guides to only $50 million of after-tax FX headwind in FY2027, which implies an assumption that current rates hold. If the dollar strengthens — which is what a higher ten-year Treasury tends to produce — the reported revenue line loses the 2 points that made FY2026 look like a 3% growth year.

The one cost line management controls is capital expenditure, and here the trajectory is unhelpful. P&G spent $4.4 billion of capital in FY2026, up from $3.8 billion in FY2025 and $3.3 billion in FY2024, or 5.1% of net sales against 4.5% a year earlier. Guidance for FY2027 is 4.5% to 5.5% of net sales, which at the guided revenue range implies $4.0 billion to $4.9 billion. Capital intensity has risen by roughly a third in five years against zero volume growth. Some of that is capacity in the emerging markets, some is the productivity programme's automation spend, and some is the supply-chain resilience investment that every multinational has been making since 2022. None of it is generating volume.

19 — Regulation & the wellness pivotLow legal risk, high regulatory risk, and a $3.8 billion bet on supplements

P&G is not a litigious company by the standards of the sectors Farstar usually covers. Its ten-K legal-proceedings disclosure is one paragraph long and lists the ordinary categories — antitrust and trade regulation, product liability, advertising, contracts, environmental issues, patent and trademark matters, labour and employment, and tax — without naming a single material proceeding. There is no equivalent of the Federal Trade Commission's monopolisation case against Amazon, no opioid-style mass tort, no patent cliff. For a company with $87 billion of revenue sold into 180 countries, that is a remarkably clean legal profile.

The regulatory risk is real but diffuse, and it operates on four fronts.

Product safety and chemical regulation. P&G's portfolio includes products that are applied to skin, ingested orally in small quantities, and used around infants. Regulators in the European Union, the United States and increasingly in Asia have been tightening rules on ingredients — fragrance allergens, preservatives, fluorides, PFAS in packaging, microplastics in rinse-off products. Each tightening requires reformulation, which costs money and can change product performance in ways consumers notice. The company's scale is an advantage here: it can afford the reformulation and the testing that a smaller competitor cannot.

Advertising and claims. P&G is one of the largest advertisers in the world at $10.2 billion a year, and every claim it makes about superiority is a potential regulatory exposure in every jurisdiction where the claim appears. This is a permanent cost of doing business in the category, not a discrete risk, but it is one of the reasons the advertising budget keeps rising: substantiating claims is part of the expense.

Environmental and packaging mandates. Extended producer responsibility regimes, recycled-content mandates and single-use-plastic restrictions are being introduced across Europe and in a growing number of US states. P&G's packaging is a material cost line and a material compliance line, and the direction of travel is toward more recycled content, more refillable formats and more fees. The company has been investing in concentrated and refillable formats for years and treats this as a competitive advantage rather than a burden, which is probably correct given that its scale lets it absorb compliance costs that would break smaller brands.

Tax. The Pillar Two global minimum tax framework and the ongoing OECD process on profit allocation affect a company with P&G's geographic footprint disproportionately. Its effective tax rate was 20.8% in FY2026 and management guides to approximately 20% for FY2027, which is stable. But the geographic mix of profit is shifting — Grooming's FY2026 margin decline was partly attributed to an increase in the effective tax rate "driven by unfavourable geographic mix" — and a continued shift of profit toward higher-tax jurisdictions would be a persistent earnings headwind.

The strategic logic of Thorne is worth stating clearly, because it is the clearest signal of where management thinks the next decade of growth comes from. P&G's own categories grow at roughly the rate of population plus price. Supplements grow faster, are consumed daily, are purchased repeatedly, and are adjacent to the Health Care segment's existing consumer. Buying a practitioner-recommended brand for 0.75 times annual free cash flow is a rational way to rent some growth in a category where P&G has no organic capability. What it is not is a transformation: at roughly $1 billion of implied revenue, Thorne is about 1.1% of P&G's sales.

20 — InnovationTwo billion dollars a year, and a superiority claim that is getting harder to prove

P&G's central strategic claim is that it competes only in categories "where performance plays a significant role in the consumer's choice of brands," and that it wins in those categories through "irresistible superiority across five key vectors — product performance, packaging, brand communication, retail execution and value." The claim is that superiority produces market growth, which produces share, which produces profit. It is a coherent theory of the firm, and the company has been executing it for a decade.

The evidence for it in FY2026 is mixed, and the mix is instructive. Where superiority is demonstrable and testable, it works. The Greater China baby care business grew double digits organically for six consecutive quarters and gained nearly five points of value share behind a diaper built with silk materials to deliver skin comfort, wrapped in a package designed to convey superiority at first touch. Pantene in Germany grew value sales 14% and gained half a point of share after reinventing its communication model around social and influencer channels, producing a four-fold increase in influencer-generated content and a tripling of reach. Those are real innovations producing real share gains.

Where superiority is not demonstrable, the theory does not hold. Family Care — Bounty and Charmin — lost 0.7 points of North American share on price cuts. Oral care organic sales were flat globally on a mid-teens decline in Greater China. Skin care lost 0.6 points of global share. Hair care lost 0.5 points. The pattern is that P&G wins where a consumer can tell the difference in use and loses where they cannot.

Management's answer to this is "constructive disruption of the entire value chain," which in practice means three things: rebuilding the content creation engine in-house so that brand communication can be produced faster and cheaper; rethinking the supply chain so that the company can serve quick-commerce and social-commerce channels with different pack sizes and faster replenishment; and applying data and AI to consumer insight so that innovation is aimed more precisely. All three are the right things to do. None of them changes the fact that a detergent molecule is a detergent molecule.

The most honest framing of P&G's innovation position is that it is strong in the categories where it matters most and irrelevant in the categories where it does not. The super-premium skin care, premium baby care and personal health care businesses have genuine technology and genuine consumer-insight advantage. The paper, detergent and family care businesses are scale businesses with brands attached. The company's portfolio is roughly evenly divided between the two, and the growth is entirely in the first.

21 — ManagementThe Jejurikar reset, and the seven thousand roles behind it

Shailesh Jejurikar became chairman of the board, president and chief executive officer on 1 January 2026, succeeding Jon Moeller, who moved to executive chairman. Jejurikar is a thirty-year P&G veteran who previously ran the Fabric & Home Care sector — the largest and most operationally complex part of the company — and before that the company's global fabric-care business. His appointment was not a change of direction; it was a promotion from within of the executive most closely associated with the productivity and cost discipline agenda.

The letter to shareowners that opens the FY2026 annual report is the clearest statement of his thinking. It identifies three changes in the external environment — media fragmentation, the transformation of the retail landscape, and five years of cumulative inflation — and four interventions in response: putting the consumer first, transforming brand building, building holistic partnerships with retailers, and creating a stronger core with "bigger, more profitable innovations."

The operating expression of that is the portfolio and productivity plan announced in June 2025. The plan has two components. The first is portfolio streamlining — exiting or divesting businesses that do not meet the strategic filter, a process that has been running for a decade and that produced the Glad joint venture dissolution in January 2026. The second is organisational: a reduction of up to 7,000 non-manufacturing overhead positions by the end of fiscal 2027, executed across the Sector Business Units, the Enterprise Markets, Corporate Functions and Global Business Services.

The financial case for the plan is straightforward: at an average fully-loaded overhead cost of roughly $120,000 per position, 7,000 roles is approximately $840 million of annualised saving, or about $0.29 per share after tax. Against FY2027 core EPS guidance of $6.89 to $7.11, that is 4% of earnings — meaningful but not transformative. The strategic case is more interesting: Jejurikar's argument is that the overhead structure was built for a company that grew 5% a year, and that a company growing 1% to 2% needs a leaner centre in order to fund the marketing and innovation that will restore growth.

There are three things to watch in assessing whether the plan is working. The first is whether the savings appear in operating margin or are reinvested. The past three years suggest reinvestment: P&G has taken 400 to 460 basis points of quarterly gross productivity savings and delivered a declining operating margin, because the savings have gone into marketing. The second is whether the restructuring disrupts execution. Cutting a fifth of the overhead base at a company whose growth depends on innovation cadence and retail execution carries genuine execution risk, and the FY2026 share data — value share roughly flat, five of ten categories holding or growing share — is consistent with a company that is managing the transition without losing ground. The third is whether the new leadership changes the capital allocation priorities. Jejurikar has publicly committed to the dividend and to the buyback, and to the $3.8 billion Thorne acquisition. There is no sign of a strategic pivot.

Management's guidance record is worth noting. P&G delivered within its going-in guidance ranges across all key metrics in FY2026 despite "headwinds not anticipated at the start of the fiscal year." That is a company that manages expectations carefully and hits them, which is a point in its favour and also the reason its guidance should be taken as a genuine forecast rather than as sandbagging. The FY2027 guide of $6.89 to $7.11 core EPS, with $0.56 per share of quantified headwinds, is consistent with that record.

22 — ValuationThe multiple depends entirely on what you think the ten-year Treasury is worth

Valuation for a mature staples franchise is not a growth exercise. It is a discount-rate exercise with a growth assumption attached, and in 2026 the discount rate is the variable that has moved. P&G earned $6.62 of GAAP diluted EPS and $6.89 of core EPS in FY2026. At $147.49, that is 22.3 times GAAP earnings and 21.4 times core earnings. On the forward numbers — our estimate of $7.00 of FY2027 core EPS, the midpoint of guidance — it is 21.1 times.

Twenty-one times earnings for a company guiding to 1.5% EPS growth is a PEG ratio of about fourteen on the guidance midpoint, or 4.2 on a three-year consensus growth rate. Neither is comfortable. But the multiple has to be assessed against the company's own history and against the risk-free rate, and those two comparisons point in opposite directions.

Against its own history, P&G has de-rated meaningfully. Its forward multiple was 24.5 times in FY2023, 24.1 times in FY2024, 23.0 times in FY2025 and 21.3 times in FY2026. Today's 20.9 times forward is the lowest in five years and roughly 15% below the five-year mean of 24.1 times. On that comparison the stock looks cheap.

Against the risk-free rate, it does not. The ten-year Treasury yields 5.31% as of 5 October 2026, its highest level since early 2002. P&G's dividend yields 2.95%. The earnings yield is 4.65% and the free cash flow yield is 4.47%. Every one of those is below the risk-free rate. An investor buying P&G for income is accepting a 236-basis-point negative spread to a government bond in exchange for a growing coupon and equity upside.

That spread is the single most important input into the valuation, and it explains why the shares have returned 0.05% over the last twelve months while Coca-Cola returned 33%. The market is not questioning P&G's quality. It is questioning the price of a bond-like cash flow in a world where the actual bond pays more.

We have valued the shares four ways, and the methods converge on a narrower range than the headlines suggest.

Dividend discount. The FY2027 dividend is approximately $4.53 per share, based on the current $4.36 run-rate plus the customary low-single-digit annual increase. At a 7.0% cost of equity — the ten-year Treasury of 5.31% plus a 0.38 beta times a 5% equity risk premium, plus a small quality adjustment — and a 4.0% terminal growth rate, the Gordon growth model produces $151. That is the method that most closely matches how the stock actually trades, and it is where our target comes from.

Free cash flow yield. FY2026 free cash flow was $15.1 billion. A 4.5% required free cash flow yield — 81 basis points above the risk-free rate — implies an equity value of $337 billion, or $145 per share. A 5.0% required yield implies $303 billion, or $131 per share. The current 4.47% yield is at the generous end of that range.

Multiple. A justified multiple approach anchors on the payout ratio and the sustainable growth rate. With a 66% payout and EPS growth of 2% to 3%, a 20-times multiple is defensible and a 24-times multiple requires growth of 4% to 5%. At 20 times FY2027 core EPS of $7.00 the shares are worth $140; at 21 times, $147; at 22 times, $154.

Sensitivity. The problem with all three of the above is that they are hypersensitive to two parameters that are not knowable. The grid below shows the same dividend discount model across the plausible range of cost of equity and terminal growth.

The scenario analysis that follows from this is narrower than for a growth company, because P&G's outcomes are bounded by the stability of its categories. We assign a 30% probability to the bear case, 45% to the base case and 25% to the bull case.

The bear case of $118 assumes organic growth of zero, no margin recovery, and a de-rating to 17 times earnings as the market concludes that a 2.95% dividend yield is not adequate compensation against a 5.31% risk-free rate. The base case of $150 assumes 2% organic growth in line with the low end of guidance, a further 30 basis points of margin decline as the input-cost headwind is only partly offset, and a 21.4-times multiple on FY2027 core EPS. The bull case of $178 assumes a genuine volume recovery in the second half, 4% organic growth, margin expansion from the restructuring savings, and a re-rating to 24 times as the market concludes that P&G's quality deserves its historical premium.

The practical conclusion is that the shares are approximately fairly valued, with a skew. The expected return of roughly 4.7% including the dividend is below what an investor can earn on a ten-year government bond. That is not a reason to short the stock — P&G's downside is bounded by its cash flow, and a fall in long rates would re-rate it immediately — but it is a reason not to own it at this price, and it is why our rating is Neutral rather than Constructive.

23 — The bull caseSix arguments we take seriously

One: the categories are non-discretionary and the brands are irreplaceable. P&G sells things people buy every week regardless of the economic cycle — detergent, diapers, toothpaste, toilet paper, shampoo. That gives it a revenue base with the lowest demand elasticity in the equity market. A recession would reduce P&G's revenue by less than it would reduce the index's, and the company would still generate $15 billion of free cash flow. In a late-cycle environment, that is worth something, and the market's willingness to pay 21 times earnings for it reflects that.

Two: the productivity programme is a genuine, quantified, controllable lever. Seven thousand roles, $1.5 to $2.0 billion of restructuring cost, and roughly $840 million of annualised saving is the largest self-help opportunity P&G has had in a decade. Unlike pricing or volume, management controls the timing and the magnitude of it. If even half of the saving reaches the operating margin rather than being reinvested, that is 40 basis points of margin expansion in FY2028 and roughly $0.15 of EPS.

Three: Greater China has turned. The region went from a mid-teens decline in oral care and a third of SK-II's sales disappearing, to 4% organic growth for the full year and 18% growth in SK-II in the March quarter. Greater China baby care has grown organically at double digits for six consecutive quarters and gained nearly five points of value share. If the reset holds, the region contributes 4% to 6% organic growth on 7% of sales, which is worth roughly 30 to 40 basis points of company organic growth against a drag of similar size two years ago. That is a swing of 60 to 80 basis points.

Four: the market share trend has inflected. Management's disclosure is that global value and volume share exited the year "roughly flat" after improving in the second half, and that 26 of the top 50 category and country combinations held or grew share. Share trends lead revenue trends by two to four quarters in consumer staples, because a brand that is holding share while taking price is a brand that will grow volume when it stops taking price. If the second-half improvement is the beginning of a trend rather than a base effect, FY2027 volume could turn positive.

Five: the balance sheet and cash flow support the dividend through anything. Free cash flow covers the dividend 1.48 times. Interest coverage is 24.6 times. Debt is 1.4 times EBITDA. The company has paid a dividend for 136 consecutive years and raised it for 70. For an income investor with a long horizon, a 2.95% yield growing at 3% to 4% with that level of coverage is a legitimate holding, and the alternative — a 5.31% Treasury with no growth and full duration risk — is not obviously better over a ten-year horizon.

Six: the multiple has already de-rated. From 24.5 times forward earnings in FY2023 to 20.9 times today is a 15% compression. Much of the bad news about flat volume and narrowing margin is therefore in the price. If the ten-year Treasury falls back toward 4% — which is where the futures market has it in twelve months — a staples franchise with a 2.95% yield and 0.38 beta would re-rate quickly, and the arithmetic is powerful: at a 7.0% cost of equity and 4.0% growth, every 50 basis points of lower required return is worth roughly 15% on the share price.

24 — The bear caseSix arguments we cannot dismiss

One: volume has been zero for two years and the company has no articulated mechanism to fix it. Organic growth of 1% is entirely price. Unit volume was zero in FY2025 and zero in FY2026. Management's FY2027 guidance of 1% to 3% organic growth, with a 30-to-50 basis point headwind from brand and product-form discontinuations, does not describe a volume recovery; it describes a continuation. And the demographic structure of P&G's categories — below-replacement birth rates, slowing household formation, saturated penetration in the developed markets — puts a structural ceiling on volume that no marketing budget can raise.

Two: the price lever is exhausted. P&G took 3% to 5% of price a year from FY2022 to FY2024, about 2% in FY2025 and 1% in FY2026. There is no evidence of further pricing capacity in the developed markets, and the Family Care share loss on lower pricing suggests the company is now on the defensive. Without price and without volume, revenue growth reduces to currency translation, which is not a business strategy.

Three: the company is paying more to stand still. Advertising expense rose $1.0 billion, or 11%, while organic growth halved. Operating margin fell 160 basis points and net margin narrowed in all five segments. Gross productivity savings of 400 to 460 basis points a quarter were entirely consumed. If the marginal dollar of marketing is producing negative incremental growth — which is what FY2026 shows — then the strategy of reinvesting productivity into brand building is not a bridge to growth; it is a treadmill.

Four: the dividend yields less than the risk-free rate. 2.95% against 5.31% is a 236-basis-point negative spread, the widest in more than a decade. The free cash flow yield of 4.47% is also below the Treasury. For a stock whose principal attraction for a large part of its shareholder base is income, that is a serious problem, and it is a problem that cannot be fixed by the company. It can only be fixed by a fall in long rates or a fall in the share price.

Five: the buyback is debt-funded and is the entire source of EPS growth. Net earnings were flat at $16.0 billion; diluted EPS rose 2% because the share count fell 1.3%. The ten-K states the repurchases were financed partly by debt issuance. Total debt is $35.0 billion and rising, current liabilities exceed current assets by $12.5 billion, and the company guides FY2027 free cash flow productivity down to 85% to 90% — meaning the gap between capital return and free cash flow widens. At some point, a company borrowing to buy back stock while its dividend yields less than a government bond is making a capital allocation statement the market may not accept indefinitely.

Six: private label is taking share in the categories with the least defence. Family Care lost 0.7 points of North American share on price cuts. Feminine Care lost 0.2 points. Store brands now hold roughly 22.5% of the staples categories with improving momentum, and the historical pattern of private label giving share back after inflation subsides has not repeated this cycle. In the categories where performance is demonstrable — super-premium skin care, premium baby care, personal health care — P&G is winning. In the categories where it is not — paper, family care, basic hair care — it is losing, and those are a substantial share of the portfolio.

25 — Risk matrixTwelve risks, ranked by probability times impact

The table below ranks the risks we consider material to the investment case. Probability and impact are scored from one to five, where one is remote or immaterial and five is near-certain or severe. The score is the product. A score of 20 or above means the risk is both likely and consequential and should be reflected in the price; a score below 8 means it is a tail to be monitored rather than a thesis.

Two observations follow from the matrix. The first is that the two highest-scoring risks — R1 and R3 — are the same risk viewed from two directions. R1 is the operating risk that volume never returns; R3 is the market risk that the multiple de-rates because volume never returns. In a mature staples franchise these two risks are highly correlated, which means an investor who is wrong about volume is likely to be wrong about the multiple as well, and the downside is compounding rather than additive. That is why our bear case of $118 is not a tail scenario.

The second is that the balance sheet is not a risk at all at current levels. R11 and R9, the two lowest-scoring entries, are the only balance-sheet items on the list, and both are manageable: debt is 1.4 times EBITDA with 24.6 times interest coverage, and the Gillette impairment is non-cash. P&G will not be forced into a distressed capital action by anything on this list. The risks are all about the growth rate and the price paid for it.

26 — CatalystsWhat we are watching, and when

27 — ConclusionNeutral at $150, on a business that is performing and a price that assumes it will

P&G is one of the best-run consumer companies in the world and one of the most fully-priced. The FY2026 results do not describe a business in trouble. They describe a business that has run out of the two levers that produced its last five years of growth — price and currency — and has not yet found the third. Unit volume was zero for the second consecutive year. Organic growth was 1%, down from 7% three years ago. Operating margin fell 160 basis points. Net margin narrowed in all five segments. And the company spent a billion dollars more on advertising to produce half the growth.

Against that, the cash generation is exceptional, the balance sheet is strong, the productivity programme is a genuine and quantified lever, Greater China has turned, and the multiple has already de-rated 15% from its FY2023 peak. This is not a broken business. It is a mature one, priced as though maturity were a temporary condition.

Our twelve-month target is $150, approximately 21.4 times our FY2027 core EPS estimate of $7.00, which is the midpoint of company guidance. That implies a price return of 1.7% and a total return of roughly 4.7% including the dividend. The ten-year Treasury pays 5.31%. An investor is being asked to accept equity risk, a 0.38 beta notwithstanding, in exchange for a total return below the risk-free rate. We rate the shares Neutral.

28 — AppendixFinancial summary tables

Fiscal years end 30 June. All segment and company figures are as reported by P&G. Market data as of 6 October 2026. Farstar estimates are identified as such.

29 — SourcesPrimary and secondary references

This report is built from primary sources wherever possible. The financial statements, segment disclosures, sales-driver tables, risk factors and restructuring details are drawn from P&G's own filings. Market data is from third-party aggregators and is dated. Where we have made an estimate or a judgement, it is labelled as a Farstar estimate in the text.

30 — DisclosureConflicts, limitations, and revision policy

Continue reading: Amazon.com — The Cost of Capacity →  ·  Oracle — The $664 Billion Promise →  ·  Meta Platforms — The Gap Between Two Numbers →